Verition Fund Management
ALXN

Verition Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Verition Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-530,600
Closed -$97.5M – 2525
2021
Q2 		$97.5M Buy
530,600
+350,700
+195% +$60.2M 0.89% 23
2021
Q1 		$27.5M Buy
179,900
+54,100
+43% +$8.37M 0.31% 38
2020
Q4 		$19.7M Buy
125,800
+122,600
+3,831% +$15.8M 0.17% 88
2020
Q3 		$366K Buy
+3,200
New +$345K 0.01% 706

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Verition Fund Management's ALXN Position: Q3 2021 in Review

Verition Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 380,182 shares — an estimated $69.8M sold.

Verition Fund Management first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $69.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Verition Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Verition Fund Management sold 380,182 Alexion Pharmaceuticals shares in Q3 2021, an estimated $69.8M.
  • Verition Fund Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Verition Fund Management's Alexion Pharmaceuticals position peaked at $69.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Verition Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.